ClinicalTrials.gg
CompletedNCT03357731Updated Jul 27, 2020Results posted

A Study of Continuous Infusions of HNO (Nitroxyl) Donor in Patients With Heart Failure and Impaired Systolic Function

A Phase 2 interventional study of HNO Donor and Nitroglycerin (NTG) in Heart Failure, Cardiac Failure and Reduced Ventricular Ejection Fraction, sponsored by Bristol-Myers Squibb. Completed at 18 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-27.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
49
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing cimlanod in Heart Failure — none open to participants now, none under way, none of them phase 3. cimlanod · Heart Failure.

Enrollment
7th of 10
49 · median 58
Started
2017
with 2 others
Phase 2
4 of 10
none open now
Registered
6th of 10
by date
Lead sponsor
10 of 10
Bristol-Myers Squibb

Among the 10 studies testing cimlanod in Heart Failure, this one is the 7th largest by enrollment, is one of 3 that started in 2017, is one of 4 in phase 2, and was the 6th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

None of the 10 studies testing cimlanod in Heart Failure is open now. The open studies under Heart Failure, anywhere →

About cimlanod

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing cimlanod in Heart Failure as a file.
02

Study summary

The purpose of this study is to evaluate the effects of BMS-986231 on systolic and diastolic parameters in patients with heart failure and low ejection fraction.

03

Conditions studied

  • Heart Failure
  • Cardiac Failure
  • Reduced Ventricular Ejection Fraction

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Heart failure with reduced (LVEF on echocardiogram of 40% or less)
  • Stable guideline directed therapy for heart failure including oral diuretics, ACEi, ARBs, ARNi, MRAs, and β blockers as tolerated, with no dose changes of these medications in the past 2 weeks
  • Have screening values of NT pro-BNP ≥ 125 pg/mL (15 pmol/L) or BNP ≥ 35 pg/mL (10 pmol/L)

Exclusion criteria

Exclusion Criteria:

  • Systolic blood pressure (SBP) \< 110 mm Hg at screening or pre-randomization
  • Heart rate \< 50 beats per minute (bpm) or > 90 bpm at screening or pre-randomization
  • Permanent Atrial Fibrillation, Atrial Flutter or having Atrial Fibrillation, Atrial Flutter
  • Estimated (eGFR) \< 15 ml/min/1.73 m2
  • Ventricular assist device or prior heart transplant
  • Prior solid organ transplant
  • Body weight \< 45 kg or ≥ 140 kg
  • Low quality echocardiographic visualization windows and image acquisition
  • Permanent paced rhythm (VVI, DDD or BiV pacing)

Other protocol defined inclusion/exclusion criteria could apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    Placebo/BMS-986231/NTG

    administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods

    Drug: HNO Donor · Drug: Nitroglycerin (NTG) · Other: Placebo

  • Experimental
    Placebo/NTG/BMS-986231

    administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods

    Drug: HNO Donor · Drug: Nitroglycerin (NTG) · Other: Placebo

  • Experimental
    NTG/Placebo/BMS-986231

    administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods

    Drug: HNO Donor · Drug: Nitroglycerin (NTG) · Other: Placebo

  • Experimental
    NTG/BMS-986231/Placebo

    administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods

    Drug: HNO Donor · Drug: Nitroglycerin (NTG) · Other: Placebo

  • Experimental
    BMS-986231/Placebo/NTG

    administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods

    Drug: HNO Donor · Drug: Nitroglycerin (NTG) · Other: Placebo

  • Experimental
    BMS-986231/NTG/Placebo

    administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods

    Drug: HNO Donor · Drug: Nitroglycerin (NTG) · Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Stroke Volume Index (SVI) Derived From the Velocity Time Integral at the Left Ventricular Outflow Tract (LVOT VTI) at the End of the 5-hour Infusion of BMS-986231, Versus Placebo

    The objective is to evaluate the effects of BMS-986231 on the left ventricular (LV) systolic function by stroke volume index (SVI) assessed by echocardiography compared to placebo.

    Time frame: at the end of the 5-hour infusion

Secondary outcomes

  1. Mean SVI Derived From LVOT VTI at the End of the 5-hour Infusion of BMS-986231, Versus NTG

    The objective is to evaluate the effects of BMS-986231 on the left ventricular (LV) systolic function by stroke volume index (SVI) assessed by echocardiography compared to NTG.

    Time frame: at the end of the 5-hour infusion

  2. Mean LVEF, Computed by Simpson's Method at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG

    Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG: LV ejection fraction

    Time frame: at the end of the 5-hour infusion

  3. Mean Cardiac Power Index at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG

    Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG: Mean LV power index

    Time frame: at the end of the 5-hour infusion

  4. Mean Diastolic Indices: E/A and E/e' Ratio at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG

    Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG: Diastolic function

    Time frame: at the end of the 5-hour infusion

  5. Mean Diastolic Indices: Annular e' Velocity at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG

    Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG: Diastolic function

    Time frame: at the end of the 5-hour infusion

  6. Mean LV Global Longitudinal Strain, Computed Using STE at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG

    Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG: LV global longitudinal strain

    Time frame: at the end of the 5-hour infusion

07

Results

Posted Jul 27, 2020

Participant flow

Participant flow — Overall Study
MilestoneSequence 1Sequence 2Sequence 3Sequence 4Sequence 5Sequence 6
Started877788
Completed period 1 (p1)877678
Completed period 2 (p2)877477
Completed876477
Not completed001311
Withdrew: Withdrew consent due to personal reasons000010
Withdrew: Acute bradycardia and hypotension000100
Withdrew: Adverse event000001
Withdrew: Hypotension001100
Withdrew: Lost to follow-up000100

Outcome measures

PrimaryMean Stroke Volume Index (SVI) Derived From the Velocity Time Integral at the Left Ventricular Outflow Tract (LVOT VTI) at the End of the 5-hour Infusion of BMS-986231, Versus Placebo

The objective is to evaluate the effects of BMS-986231 on the left ventricular (LV) systolic function by stroke volume index (SVI) assessed by echocardiography compared to placebo.

Time frame:
at the end of the 5-hour infusion
Reported as:
Mean · mL/m^2
Mean Stroke Volume Index (SVI) Derived From the Velocity Time Integral at the Left Ventricular Outflow Tract (LVOT VTI) at the End of the 5-hour Infusion of BMS-986231, Versus Placebo
mL/m^2Placebo (PBO)BMS-986231Nitroglycerin (NTG)
Mean Stroke Volume Index (SVI) Derived From the Velocity Time Integral at the Left Ventricular Outflow Tract (LVOT VTI) at the End of the 5-hour Infusion of BMS-986231, Versus Placebo29.545 ± 7.024328.721 ± 9.0174—
Statistical analysis
  • Placebo (PBO) vs BMS-986231 · Kenward-Roger degree of freedom · p = 0.027 · Mean difference (net): -2.150 · 95% CI -4.0432 to -0.2570The modelled mean difference uses treatment sequence and difference of baselines as a covariates of the treatment effect.
SecondaryMean SVI Derived From LVOT VTI at the End of the 5-hour Infusion of BMS-986231, Versus NTG

The objective is to evaluate the effects of BMS-986231 on the left ventricular (LV) systolic function by stroke volume index (SVI) assessed by echocardiography compared to NTG.

Time frame:
at the end of the 5-hour infusion
Reported as:
Mean · mL/m^2
Mean SVI Derived From LVOT VTI at the End of the 5-hour Infusion of BMS-986231, Versus NTG
mL/m^2Placebo (PBO)BMS-986231Nitroglycerin (NTG)
Mean SVI Derived From LVOT VTI at the End of the 5-hour Infusion of BMS-986231, Versus NTG—28.721 ± 9.017427.811 ± 7.9712
Statistical analysis
  • BMS-986231 vs Nitroglycerin (NTG) · Kenward-Roger degree of freedom · p = 0.846 · Mean difference (net): 0.193 · 95% CI -1.8176 to 2.2042The modelled mean difference uses treatment sequence and difference of baselines as a covariates of the treatment effect.
SecondaryMean LVEF, Computed by Simpson's Method at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG

Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG: LV ejection fraction

Time frame:
at the end of the 5-hour infusion
Reported as:
Mean · Percentage of blood pumped from the LV
Mean LVEF, Computed by Simpson's Method at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG
Percentage of blood pumped from the LVPlacebo (PBO)BMS-986231Nitroglycerin (NTG)
Mean LVEF, Computed by Simpson's Method at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG31.9 ± 7.1532.8 ± 8.2433.5 ± 7.33
Statistical analysis
  • Placebo (PBO) vs BMS-986231 · Kenward-Roger degree of freedom · p = 0.177 · Mean difference (net): 1.3 · 95% CI -0.62 to 3.19The modelled mean difference uses treatment sequence and difference of baselines as a covariates of the treatment effect.
  • BMS-986231 vs Nitroglycerin (NTG) · Kenward-Roger degree of freedom · p = 0.839 · Mean difference (net): -0.1 · 95% CI -1.08 to 0.88The modelled mean difference uses treatment sequence and difference of baselines as a covariates of the treatment effect.
SecondaryMean Cardiac Power Index at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG

Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG: Mean LV power index

Time frame:
at the end of the 5-hour infusion
Reported as:
Mean · watts per square meter (W/m^2)
Mean Cardiac Power Index at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG
watts per square meter (W/m^2)Placebo (PBO)BMS-986231Nitroglycerin (NTG)
Mean Cardiac Power Index at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG0.4122 ± 0.144040.3427 ± 0.104630.3568 ± 0.09184
Statistical analysis
  • Placebo (PBO) vs BMS-986231 · Kenward-Roger degree of freedom · p = 0.007 · Mean difference (net): -0.0977 · 95% CI -0.16634 to -0.02915The modelled mean difference uses treatment sequence and difference of baselines as a covariates of the treatment effect.
  • BMS-986231 vs Nitroglycerin (NTG) · Kenward-Roger degree of freedom · p = 0.103 · Mean difference (net): -0.0371 · 95% CI -0.08243 to 0.00814The modelled mean difference uses treatment sequence and difference of baselines as a covariates of the treatment effect.
SecondaryMean Diastolic Indices: E/A and E/e' Ratio at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG

Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG: Diastolic function

Time frame:
at the end of the 5-hour infusion
Reported as:
Mean · Ratio
Mean Diastolic Indices: E/A and E/e' Ratio at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG
RatioPlacebo (PBO)BMS-986231Nitroglycerin (NTG)
E/A ratio0.80 ± 0.2780.73 ± 0.2700.71 ± 0.310
E/e' ratio9.42 ± 4.1027.00 ± 2.4647.81 ± 2.652
Statistical analysis
  • Placebo (PBO) vs BMS-986231 · Kenward-Roger degree of freedom · p = 0.003 · Mean difference (net): -0.13 · 95% CI -0.205 to -0.051The modelled mean difference uses treatment sequence and difference of baselines as a covariates of the treatment effect.
  • BMS-986231 vs Nitroglycerin (NTG) · Kenward-Roger degree of freedom · p = 0.904 · Mean difference (net): 0.00 · 95% CI -0.051 to 0.057The modelled mean difference uses treatment sequence and difference of baselines as a covariates of the treatment effect.
  • Placebo (PBO) vs BMS-986231 · Kenward-Roger degree of freedom · p = 0.006 · Mean difference (net): -1.66 · 95% CI -2.763 to -0.549The modelled mean difference uses treatment sequence and difference of baselines as a covariates of the treatment effect.
  • BMS-986231 vs Nitroglycerin (NTG) · Kenward-Roger degree of freedom · p = 0.503 · Mean difference (net): -0.27 · 95% CI -1.085 to 0.550The modelled mean difference uses treatment sequence and difference of baselines as a covariates of the treatment effect.
SecondaryMean Diastolic Indices: Annular e' Velocity at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG

Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG: Diastolic function

Time frame:
at the end of the 5-hour infusion
Reported as:
Mean · cm/sec
Mean Diastolic Indices: Annular e' Velocity at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG
cm/secPlacebo (PBO)BMS-986231Nitroglycerin (NTG)
Mean Diastolic Indices: Annular e' Velocity at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG7.18 ± 2.4678.07 ± 2.3337.18 ± 2.143
Statistical analysis
  • Placebo (PBO) vs BMS-986231 · Kenward-Roger degree of freedom · p = 0.994 · Mean difference (net): -0.00 · 95% CI -0.827 to 0.820The modelled mean difference uses treatment sequence and difference of baselines as a covariates of the treatment effect.
  • BMS-986231 vs Nitroglycerin (NTG) · Kenward-Roger degree of freedom · p = 0.073 · Mean difference (net): 0.48 · 95% CI -0.049 to 1.013The modelled mean difference uses treatment sequence and difference of baselines as a covariates of the treatment effect.
SecondaryMean LV Global Longitudinal Strain, Computed Using STE at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG

Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG: LV global longitudinal strain

Time frame:
at the end of the 5-hour infusion
Reported as:
Mean · Percentage of blood pumped from the LV
Mean LV Global Longitudinal Strain, Computed Using STE at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG
Percentage of blood pumped from the LVPlacebo (PBO)BMS-986231Nitroglycerin (NTG)
Mean LV Global Longitudinal Strain, Computed Using STE at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG-11.98 ± 2.860-11.94 ± 3.458-11.36 ± 3.067
Statistical analysis
  • Placebo (PBO) vs BMS-986231 · Kenward-Roger degree of freedom · p = 0.705 · Mean difference (net): 0.15 · 95% CI -0.670 to 0.976The modelled mean difference uses treatment sequence and difference of baselines as a covariates of the treatment effect.
  • BMS-986231 vs Nitroglycerin (NTG) · Kenward-Roger degree of freedom · p = 0.105 · Mean difference (net): -0.68 · 95% CI -1.504 to 0.151The modelled mean difference uses treatment sequence and difference of baselines as a covariates of the treatment effect.

Adverse events

Collected over From first dose to 30 days post last dose (approximately 3 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (PBO)0/40 (0%)1/40 (2.5%)2/40 (5%)
BMS-9862310/42 (0%)0/42 (0%)12/42 (28.6%)
Nitroglycerin (NTG)0/44 (0%)1/44 (2.3%)10/44 (22.7%)
Most frequent serious events
Most frequent serious events
EventPlacebo (PBO)BMS-986231Nitroglycerin (NTG)
Cholecystitis acuteHepatobiliary disorders1/400/420/44
SyncopeNervous system disorders0/400/421/44
Most frequent other events
Most frequent other events
EventPlacebo (PBO)BMS-986231Nitroglycerin (NTG)
HeadacheNervous system disorders2/4010/427/44
HypotensionVascular disorders0/405/423/44

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Overall Participants
<=18 years0
Between 18 and 65 years20
>=65 years25
Age, Continuous
Age, Continuous(Years)Overall Participants
Mean63.7 ± 12.35
Sex: Female, Male
Sex: Female, Male(Participants)Overall Participants
Female8
Male37
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Overall Participants
Hispanic or Latino0
Not Hispanic or Latino2
Unknown or Not Reported43
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Overall Participants
American Indian or Alaska Native0
Asian3
Native Hawaiian or Other Pacific Islander0
Black or African American1
White40
More than one race0
Unknown or Not Reported1
08

Study locations

18 sites
  • Orange County Research Center
    Tustin, California 92780, United States
  • Northwestern Medicine
    Chicago, Illinois 60611, United States
  • Indiana University School of Medicine-Indianapolis
    Indianapolis, Indiana 46202-1218, United States
  • Brigham and Womens Hospital
    Boston, Massachusetts 02115, United States
  • Duke Advanced Heart and Lung Failure Clinic
    Durham, North Carolina 27710, United States
  • Inova Heart and Vascular Institute
    Falls Church, Virginia 22042, United States
  • Local Institution
    Nagoya, Aichi 466-8560, Japan
  • Local Institution
    Kawasaki, Kanagawa 211-8533, Japan
  • Local Institution
    Suita-shi, Osaka 5650871, Japan
  • Local Institution
    Groiningen, 9713GZ, Netherlands
  • Local Institution
    Edinburgh, EH16 4SA, United Kingdom
  • Local Institution
    Glasgow, G4 0SF, United Kingdom
  • Local Institution
    Glasgow, G429LF, United Kingdom
  • Local Institution
    Glasgow, G51 4TF, United Kingdom
  • Local Institution
    Harrow, HA1 3UJ, United Kingdom
  • Local Institution
    London, SE1 1YR, United Kingdom
  • Local Institution
    London, sw17 0re, United Kingdom
  • Local Institution
    London, SW3 6NP, United Kingdom
09

References and documents

Publications

  • Felker GM, Borentain M, Cleland JG, DeSouza MM, Kessler PD, O'Connor CM, Seiffert D, Teerlink JR, Voors AA, McMurray JJV. Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure. Eur J Heart Fail. 2019 Aug;21(8):1022-1031. doi: 10.1002/ejhf.1504. Epub 2019 Jun 6. PubMed 31168885 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in May 2019, 17 months.

Results were first posted in Jul 2020, 1 year 2 months after primary completion.

Of 74 industry-sponsored phase 2 interventional studies under Heart Failure, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 31. This study's 17 months is below that.

Counting every sponsor, half of 185 studies reached it within 29 months; a quarter within 17 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2017
First posted
Nov 30, 2017
StartActual
Nov 30, 2017
Primary completionActual
May 10, 2019
CompletionActual
May 10, 2019
Results first posted
Jul 27, 2020
Last update
Jul 27, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03357731
Responsible party
Sponsor
First posted
Nov 30, 2017
Start date
Nov 30, 2017
Primary completion
May 10, 2019
Completion
May 10, 2019
Results posted
Jul 27, 2020
Last update
Jul 27, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cimlanod

Start the discussion